NOCIL reported a 20% revenue jump to INR 403 crore for the first quarter, backed by strong volume growth. Despite the performance, analysts have maintained a 'Hold' rating on the stock, citing concerns over future demand moderation and raw material price volatility.
NOCIL, a major player in the rubber chemicals sector, has posted a strong financial performance for the first quarter of fiscal year 2027. The company recorded a revenue of INR 403 crore, marking a 20% increase compared to the same period last year. Profit growth was even more notable, with net profit surging 61% to INR 28 crore. This performance was driven by an improved product mix, 9% volume growth, and operational efficiency, which pushed the EBITDA margin to 11.2%, a rise of 210 basis points year-over-year.
Despite these positive results, brokerage firm Prabhudas Lilladher has maintained a 'Hold' rating on the stock with a target price of INR 179. The caution reflects potential challenges the company may face in the coming quarters. Analysts have pointed to the risk of demand moderation and uncertainties regarding raw material availability and pricing, which are critical factors for a chemical manufacturer.
Expansion and Future Projects
The company is actively investing in growth to support its long-term strategy. NOCIL is currently working on an additional INR 130 crore brownfield capital spending project at its Dahej facility, which is expected to be completed by the first half of fiscal year 2028. This expansion is designed to build on existing capacity.
Additionally, the company is testing its new TDQ antioxidant product with customers. Management expects this product to start contributing to commercial revenue by the fourth quarter of fiscal year 2027, provided it clears all necessary customer qualification processes. Looking ahead, the management has provided revenue guidance for fiscal year 2027 in the range of INR 14 billion to INR 16 billion, targeting 10% volume growth.
Sector Dynamics and Risks
NOCIL operates in a sector that is sensitive to global trade and pricing. A significant development has been the government's decision to impose a five-year anti-dumping duty on sulphenamide accelerators imported from China, the US, and the EU. This move is expected to provide some relief from intense import pricing pressure, which had previously hurt domestic manufacturers.
However, investors should remain aware of persistent risks. The company’s financial health remains tied to raw material price volatility, which can quickly change profit margins. Furthermore, the timing of customer approvals for new product lines, such as the TDQ antioxidant project, remains a key variable for growth. The stock is currently trading at approximately 26 times its estimated earnings per share for fiscal year 2028, and the market will be watching whether NOCIL can sustain its margin expansion amidst broader demand shifts in the rubber chemical industry.